Sahin O et al., 2025-03-26: X-ray-excited photodynamic study with a methylene blue-containing nanoscintillator reporting hallmarks of immunogenic cell death (calreticulin exposure) and, with anti-PD1, regression of a non-irradiated distant tumour – the clearest primary evidence that methylene-blue photodynamic killing can engage antitumour immunity.
pYSMs generate singlet oxygen species in vitro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to the cell membrane
Sahin O et al., 2025-03-26: X-ray-excited photodynamic study with a methylene blue-containing nanoscintillator reporting hallmarks of immunogenic cell death (calreticulin exposure) and, with anti-PD1, regression of a non-irradiated distant tumour – the clearest primary evidence that methylene-blue photodynamic killing can engage antitumour immunity. C6 Sahin 2025. Study type: in vitro plus in vivo pancreatic tumour xenograft in mice with an abscopal (two-tumour) design. Country: USA (MD Anderson and Rice University). Agent: PEGylated Y2O3:Eu@SiO2-methylene blue nanoscintillator (pYSM), intravenous; 10 Gy x-ray excitation; combined with anti-PD1. Funder: US NCI (P30 CA015083, R01 CA257241, 75N91019C00016, P30 CA016672, R01 CA155446, R01 DE028105). Conflicts: none declared in the record. Comparator: irradiation alone, XPDT alone, and combination arms. NOTE: methylene blue is a component of a nanoscintillator, not free drug. Study type: animal.
